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a  b  s  t  r  a  c  t
HPV  Direct  Flow  CHIP  is  a newly  developed  test  for identifying  18  high-risk  and  18  low-risk  human  papil-
lomavirus  (HPV)  genotypes.  It is  based  on  direct  PCR  from  crude-cell  extracts,  automatic  ﬂow-through
hybridization,  and  colorimetric  detection.  The  aim  of  this  study  was  to evaluate  the  performance  of HPV
Direct  Flow  CHIP  in  the  analysis  of 947  samples  from  routine  cervical  screening  or the  follow-up  of abnor-
mal  Pap  smears.  The  specimens  were  dry  swab  samples,  liquid-based  cytology  samples,  or  formalin-ﬁxed
parafﬁn-embedded  tissues.  The  genotype  distribution  was  in  agreement  with  known  epidemiological
data  for  the  Spanish  population.  Three  different  subgroups  of  the  samples  were  also  tested  by Linear
Array  (LA)  HPV  Genotyping  Test  (n  = 108),  CLART  HPV2  (n = 82), or Digene  Hybrid  Capture  2 (HC2)  HPV
DNA  Test  (n = 101).  HPV  positivity  was  73.6%  by  HPV  Direct  Flow  CHIP  versus  67%  by LA,  65.9%  by  HPVinear Array
LART HPV2
PV Direct Flow CHIP
Direct  Flow  CHIP  versus  59.8%  by  CLART,  and  62.4%  by HPV  Direct  Flow  CHIP  versus  42.6%  by HC2.  HPV
Direct  Flow  CHIP  showed  a  positive  agreement  of  88.6%  with  LA (k = 0.798),  87.3% with  CLART (k =  0.818),
and  68.2%  with  HC2  (k =  0.618).  In  conclusion,  HPV  Direct  Flow  CHIP  results  were  comparable  with  those
of  the  other  methods  tested.  Although  further  investigation  is needed  to  compare  the  performance  of
this new  test  with  a gold-standard  reference  method,  these  preliminary  ﬁndings  evidence  the  potential
value  of  HPV  Direct  Flow  CHIP  in HPV  vaccinology  and  epidemiology  studies. This is an open-access article distributed under the terms of the Creative
ommons Attribution License, which permits unrestricted use, distribution and
eproduction in any medium, provided the original author and source are credited.
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1. Introduction
Cervical cancer is the third most common cancer among women
and the second female cancer-related cause of death worldwide
(Jemal et al., 2011). It has been extensively proven that persis-
tent human papillomavirus (HPV) infection is necessary for the
development of cervical intraepithelial lesions and invasive carci-
noma (Bosch et al., 2002; Walboomers et al., 1999). Although most
HPV infections resolve spontaneously, persistence of the so-called
high-risk genotypes (Munoz et al., 2003) is directly linked to the
malignant progression of the lesions (Kjaer et al., 2002; Remmink
et al., 1995; Wallin et al., 1999), with HPV 16 and 18 accounting for
approximately 70% of all cervical cancers (IARC, 2005; Munoz et al.,
2006).
reserved.
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HPV testing offers greater sensitivity for the early detection of
re-cancerous cervical lesions in comparison to Pap smears and
as been recommended as a triage tool for efﬁcient patient man-
gement (Almonte et al., 2011; Saslow et al., 2012; Smith et al.,
006). It has been approved by several countries as the ﬁrst-line
ystem for cervical cancer screening (Almonte et al., 2011; Anttila
t al., 2009; Gustafsson et al., 1997; Peto et al., 2004).
Two different HPV vaccines are currently on the market and are
eing introduced in several countries as part of their vaccination
rograms: Cervarix® (GlaxoSmithKline, Rixensart, Belgium), which
rotects against HPV 16 and 18 (Harper et al., 2006), and Gardasil®
Sanoﬁ Pasteur MSD, Lyon, France), which targets HPV 6, 11, 16,
nd 18 (Garland et al., 2007). Cross-protection has been observed
or other HPV genotypes not included in these vaccines (Ochi et al.,
008; Paavonen et al., 2009; Wheeler et al., 2009). Sensitive detec-
ion of the different genotypes is therefore important for evaluating
he effectiveness of vaccines and the overall protection provided
gainst HPV. Viral genotyping is also an important tool in studies
f the transmission, epidemiology, and natural history of HPV.
Routine HPV detection programs mainly use commercially
vailable methods consisting of either viral DNA capture followed
y signal ampliﬁcation or PCR reactions that speciﬁcally target L1-
ene viral sequences. The Digene Hybrid Capture 2 (HC2) HPV DNA
est (Qiagen, Gaithersburg, MD)  detects 13 high-risk and 5 low-risk
enotypes and is based on the binding of cocktail RNA probes to HPV
NA sequences, capturing the RNA-DNA dimmers and amplifying
he signal. Other systems are based on L1 ampliﬁcation followed
y reverse dot/line blot hybridization to type-speciﬁc probes, such
s INNO-LiPA (Innogenetics NV, Gent, Belgium), which uses SPF10
rimers and identiﬁes 28 genotypes (Kleter et al., 1999). PGMY
rimers are also included in the L1 region and different assays based
n these are available, including CLART HPV2 (Genomica, Madrid,
pain), which identiﬁes 35 genotypes (Pista et al., 2011), and the
inear Array (LA) HPV Genotyping Test (Roche Molecular Systems,
lameda, CA) which detects 37 genotypes (Castle et al., 2008).
Various HPV detection systems, including HC2, do not identify
he speciﬁc genotype(s) present in the sample, and their results
ave a limited usefulness as they can only be reported as high-
isk positive, low-risk positive, or high-risk + low-risk positive.
n the other hand, sensitive genotype-speciﬁc detection systems
llow the deﬁnition of epidemiological patterns, prognostic pre-
ictions based on HPV type-speciﬁc infection, the monitoring
f viral persistence, and the evaluation of vaccine efﬁcacy and
ross-protection (Kjaer et al., 2010; Meijer et al., 2009). These
dvantages are important for compliance with the new ASCCP
uidelines (Saslow et al., 2012), which establish distinct man-
gement strategies as a function of genotype, e.g.,  colposcopy in
atients negative for intraepithelial lesion but positive for genotype
6 or 18.
HPV Direct Flow CHIP (Master Diagnóstica, Granada, Spain) is
 new commercially available product for sensitive HPV detection
nd genotyping and is CE-IVD marked in compliance with Euro-
ean Union diagnostic medical device manufacturing standards.
he direct PCR system allows [GP5+/GP6+]-based multiplex ampli-
cation from crude-cell extracts and does not require previous
NA extraction. The assay detects 18 high-risk or putative high-
isk genotypes (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59,
6, 68, 73, and 82MM4) and 18 low-risk genotypes (6, 11, 40, 42, 43,
4, 54, 55, 61, 62, 67, 69, 70, 71, 72, 81, 84, and 89). The analytical
ensitivity of the test was validated after successful participation in
he 2011 WHO  HPV LabNet Proﬁciency Study, which demonstrated
00% agreement with reference values in 43 samples evaluated at
ifferent concentrations (from 5 to 500 GE) in the setting of single
nd multiple infections. Furthermore, no cross-reactivity among
enotypes was observed; therefore, the analytical speciﬁcity for
hese samples was 100% (manuscript in preparation).irological Methods 193 (2013) 9– 17
The purpose of the present study was to determine the accu-
racy of the new test by analysis of 947 cervical samples and
comparison with the widely used HC2 system and similar PCR L1-
based commercial assays, LA and CLART, investigating the genotype
prevalence, infection rates, distribution by diagnostic group, and
agreement among methods.
2. Materials and methods
2.1. Sample collection and experimental design
Cervical specimens (n = 947) were collected at random during
routine gynecological screening or the follow-up of abnormal Pap
smears at nine gynecological centers in southern and central Spain
from 2010 through 2012. Samples were only eligible for inclusion
in the study when: (i) informed consent had been signed, (ii) age
and gynecological record were known, (iii) cytopathological and/or
histopathological analyses were performed, and (iv) a positive sig-
nal for the internal ampliﬁcation control (human beta-globin) was
obtained when tested by HPV Direct Flow CHIP. Pathology reports
were compiled and classiﬁed according to the Bethesda System for
reporting cervical cytology and histology (Solomon et al., 2002)
as: negative for intraepithelial lesion (NILM), atypical squamous
cells of undetermined signiﬁcance (ASCUS), low-grade squamous
intraepithelial lesion (LSIL), high-grade squamous intraepithelial
lesion (HSIL), or cervical carcinoma. All 947 samples were analyzed
by HPV Direct Flow CHIP in the laboratories of Master Diagnóstica.
The distribution of the different specimens was: 546 dry swabs, 215
liquid-based cytology specimens in PreservCyt® solution (Cytyc,
Marlborough, MA,  USA); 101 liquid-based cytology specimens in
STM transport media, using the Qiagen collection device (Qiagen,
Hilden, Germany); and 85 formalin-ﬁxed parafﬁn-embedded tissue
sections.
For comparative analysis with other commercial systems, the
following three centers also applied their habitual HPV detec-
tion method to their selected samples: (i) Ramón y Cajal Hospital
(Madrid, Spain), which analyzed their 108 liquid-based cytology
samples in PreservCyt® solution by LA, (ii) 12 de Octubre Univer-
sity Hospital (Madrid, Spain), which analyzed their 82 liquid-based
cytology samples in PreservCyt® solution by CLART, and (iii) Vir-
gen del Rocío University Hospital (Sevilla, Spain), which analyzed
their 101 liquid-based cytology samples in STM transport media by
HC2. In these centers, each sample was divided into two aliquots
for subsequent blinded testing: the ﬁrst aliquot was  tested with
the corresponding system at the center (for details see Sections
2.2–2.4), and the second aliquot, with unlabelled cell-extracts, was
tested by HPV Direct Flow CHIP at the laboratory of Master Diag-
nóstica, followed by a comparison of the results.
2.2. HPV detection and genotyping by HPV Direct Flow CHIP
For the initial HPV testing, all 947 specimens in the study were
analyzed by the HPV Direct Flow CHIP system, which includes a
[GP5+/GP6+]-based PCR, automatic reverse dot blot hybridization,
and read-out. An additional fragment (268 bp) of the beta-globin
gene is co-ampliﬁed during the multiplex PCR to assure the quality
of the input starting material. The HPV ampliﬁcation was carried
out by direct PCR from crude-cell extracts following the manufac-
turer’s instructions (Master Diagnóstica, Granada, Spain). Brieﬂy,
dry swab samples were rinsed in 400 L sterile phosphate-buffered
saline (PBS), the cell suspensions were centrifuged at 110 × g
(Heraeus Biofuge Pico- Kendro Laboratory Products, Sollentum,
Germany) for 1 min, and the pellets were dissolved in 30–50 L PBS
buffer. For liquid-based cytology samples, the cells were allowed to
settle, 200 L of the suspension were centrifuged and, after rinsing
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he pellet in 400 L PBS, the cells were dissolved in 30–50 L PBS
uffer. Formalin-ﬁxed parafﬁn-embedded specimens (1–3 sec-
ions, 5 m thickness) were placed in a solution containing 60 L
f Lysis Buffer (Master Diagnóstica, Granada, Spain) with 1.5 L
f DNA Release (Master Diagnóstica, Granada, Spain) and digested
n the MJ  MiniTM Thermal Cycler (Bio-Rad, Hercules, CA, USA) for
0 min  at 60 ◦C, followed by inactivation at 98 ◦C for 10 min. For all
hree types of specimen, the ﬁnal ampliﬁcation reaction included
3 L of the master mix  supplied, 1 L of Phire® Hot Start II DNA
olymerase (Thermo Fisher Scientiﬁc, Vantaa, Finland), and 6 L of
ither crude-cell extract or lysated tissue as DNA template. Ampli-
cation cycling conditions in the MJ  MiniTM Thermal Cycler were:
 min  of denaturation at 98 ◦C; 5 cycles of denaturation at 98 ◦C for
 s, annealing at 42 ◦C for 5 s, and elongation at 72 ◦C for 10 s; 45
ycles of denaturation at 98 ◦C for 5 s, annealing at 60 ◦C for 5 s and
longation at 72 ◦C for 10 s; and ﬁnal elongation at 72 ◦C for 1 min.
iotinylated amplicons were denatured for 5 min  at 95 ◦C, cooled
n an ice bath for 2 min, and hybridized to HPV CHIP membranes
ontaining immobilized probes for hybridization control, beta-
lobin gene, HPV-consensus sequences, and genotype-speciﬁc
PV detection. The hybridization was performed automatically in
ets of 15 samples using the e-BRID SystemTM (Master Diagnóstica,
ranada, Spain), which allows the DNA target molecules to cross
he membrane and bind to the complementary probes. Colori-
etric detection was carried out by adding NBT-BCIP substrates
hat detect alkaline phosphatase activity, creating insoluble purple
recipitates. The entire process, from the start to the ﬁnal read-out,
as completed in less than three hours.
.3. HPV detection and genotyping by Linear Array HPV
enotyping Test
The LA HPV Genotyping Test was applied at the Ramón y Cajal
ospital (Madrid, Spain) in 108 liquid-based cytology samples in
reservCyt® solution. The assay qualitatively identiﬁes 37 HPV
enotypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53,
4, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81,
2MM4, 82IS39, 83, 84, and 89). An additional primer pair tar-
eting beta-globin is also included in the LA system as internal
mpliﬁcation control. Tests were performed following the man-
facturer’s instructions. Brieﬂy, DNA was puriﬁed automatically
n the COBAS® AmpliPrep device (Roche Diagnostics, Mannheim,
ermany), starting from 800 L of cervical sample. Puriﬁed DNA
as used as the template to amplify a 450 bp fragment from
he L1 viral region in a conventional thermocycler (GeneAmp®
CR System 9700, Applied Biosystems, Foster, CA, USA). Dena-
ured biotinylated amplicons were hybridized to genotype-speciﬁc
robes in strip membranes using the Proﬁblot T48 automatic sys-
em (Tecan Trading, Männedorf, Switzerland) and Linear Array
etection Kit (Roche Molecular Systems, Alameda, CA, USA). The
esults were obtained after colorimetric detection and visual anal-
sis of the strips, consulting the reference guide provided.
.4. HPV detection and genotyping by CLART HPV2
The CLART HPV2 test was applied at the 12 de Octubre Univer-
ity Hospital (Madrid, Spain) to 82 liquid-based cytology samples
n PreservCyt® solution (Cytyc, Marlborough, MA,  USA). This assay
dentiﬁes 35 HPV genotypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42,
3, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73,
1, 82MM4, 83, 84, 85, and 89). The system includes a control for
he presence of genomic DNA as well as genotype-speciﬁc probes.
amples were processed in accordance with the manufacturer’s
rotocol, and the DNA was puriﬁed automatically by using the
IAamp DNA Mini QIAcube kit (Qiagen, Hilden, Germany). In brief,
uriﬁed DNA was used to perform PGMY-based ampliﬁcation in airological Methods 193 (2013) 9– 17 11
GeneAmp® PCR System 9700 thermocycler, the biotinylated PCR
products were hybridized to low-density microarrays, and insolu-
ble precipitates were automatically detected and analyzed by the
SAICLART® processing software (Genomica, Madrid, Spain).
2.5. HPV detection by Hybrid Capture 2 HPV DNA Test
The Hybrid Capture 2 HPV DNA Test was  applied at the Vir-
gen del Rocío University Hospital (Sevilla, Spain) in 101 samples
preserved in STM transport media (Qiagen, Hilden, Germany),
following the manufacturer’s instructions. This assay detects 13
high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and 5
low-risk (6, 11, 42, 43, 44) HPV genotypes. Brieﬂy, viral DNA was
released by cell lysis, followed by incubation with a cocktail of HPV
RNA probes, antibody-mediated dimmer capture, and AP chemi-
luminescent detection. Specimens with an RLU/CO ratio ≥1 were
considered positive.
2.6. Statistical analysis
The structure of the data was studied by descriptive analysis.
Sample sizes, sample type, HPV positivity, and multiple infection
proﬁles were described. Chi-square tests were used to analyze the
relationship of these with age and diagnostic groups. Statistically
signiﬁcant differences, overall agreement, and positive agreement
were determined between the results of HPV Direct Flow CHIP and
those of LA, CLART, and HC2. Cohen’s Kappa coefﬁcient (Landis and
Koch, 1977) was  also calculated as a measure of the agreement
between two  methods and as an indication of the accuracy of the
classiﬁcation output after accounting for the random portion. The
McNemar chi-square test (Altman, 1999), which analyzes signif-
icant differences between assays in matched-pair data, was used
to study statistically signiﬁcant differences between assays in the
detection of HPV infections. For the pairwise comparisons, only
genotypes identiﬁed by both methods were considered for the cal-
culation of agreement. SPSS version 19 (IBM, Chicago, IL, USA) was
used for the statistical analyses, which were performed at a 5%
signiﬁcance level.
3. Results
3.1. Study patients and HPV positivity among the 947 samples
tested by HPV Direct Flow CHIP
The mean age of all patients studied was 35.5 years (standard
deviation [s.d.] of 10.84 years, range 15–90 years). The mean age
was 37.3 years (s.d. 10.94) for the HPV-negative patients and
34.4 years (s.d. 10.63) for the HPV-positive patients. The distribu-
tion of diagnostic groups was: 45.4% negative for intraepithelial
lesions, 21.0% atypical squamous cells of undetermined signif-
icance, 24.9% low-grade squamous intraepithelial lesions, 7.2%
high-grade squamous intraepithelial lesions, and 1.5% cervical
carcinomas.
HPV positivity was  detected in 61.5% (582/947) of the sam-
ples studied by HPV Direct Flow CHIP. Out of these 582 positive
samples, 572 were correctly genotyped, whereas 10 were posi-
tive for the HPV-consensus probe but did not hybridize to any
genotype-speciﬁc probe. HPV infection was signiﬁcantly age-
related, observing the highest HPV infection rate (71.4%) in the
youngest age group (<30 years) (chi-square = 20.178, p < 0.001).
HPV infection rates were signiﬁcantly higher with greater disease
severity, being 37.7% (162/430) in patients negative for intraepithe-
lial lesions, 62.8% (125/199) in patients with atypical squamous
cells of undetermined signiﬁcance, 90.3% (213/236) in those
with low-grade squamous intraepithelial lesions, 100% (68/68)
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Table  1
Distribution of genotypes identiﬁed by HPV Direct Flow CHIP with respect to all HPV positive samples for each diagnosis group. n: number of samples detected for the
corresponding genotype; %: coefﬁcient of samples positive for the corresponding genotype/all the samples HPV+ included in the group. Cytology category (Bethesda): NILM
(negative for intraepithelial lesion or malignancy); ASCUS (atypical squamous cells of undetermined signiﬁcance); LSIL (low grade squamous intraepithelial lesion); HSIL
(high  grade squamous intraepithelial lesion); CxCa (cervical carcinoma).
HPV genotypes
6 11 16 18 26 31 33 35 39 40 42 43 45 51 52 53 54
NILM (n = 162)
N 23 9 36 16 0 10 6 8 4 4 21 8 13 9 15 11 16
%  14.2 5.6 22.2 9.9 0.0 6.2 3.7 4.9 2.5 2.5 13.0 4.9 8.0 5.6 9.3 6.8 9.9
ASCUS (n = 125)
N 24 6 34 11 2 14 6 8 4 3 5 7 9 5 11 6 6
%  19.2 4.8 27.2 8.8 1.6 11.2 4.8 6.4 3.2 2.4 4.0 5.6 7.2 4.0 8.8 4.8 4.8
LSIL  (n = 213)
N 49 12 94 26 3 27 17 20 12 13 35 18 19 13 30 21 9
%  23.0 5.6 44.1 12.2 1.4 12.7 8.0 9.4 5.6 6.1 16.4 8.5 8.9 6.1 14.1 9.9 4.2
HSIL  (n = 68)
N 13 2 47 4 1 7 2 9 2 2 5 3 4 7 8 1 2
%  19.1 2.9 69.1 5.9 1.5 10.3 2.9 13.2 2.9 2.9 7.4 4.4 5.9 10.3 11.8 1.5 2.9
CxCa  (n = 14)
N 5 2 11 3 0 1 1 1 1 0 4 1 4 0 3 0 0
%  35.7 14.3 78.6 21.4 0.0 7.1 7.1 7.1 7.1 0.0 28.6 7.1 28.6 0.0 21.4 0.0 0.0
Total  (n = 582)
N 114 31 222 60 6 59 32 46 23 22 70 37 49 34 67 39 33
%  19.6 5.3 38.1 10.3 1.0 10.1 5.5 7.9 4.0 3.8 12.0 6.4 8.4 5.8 11.5 6.7 5.7
HPV  genotypes
56 58 59 61 66 67 68 69 70 71 72 73 82MM4 84 89 44/55 62/81
NILM (n = 162)
N 11 6 9 3 7 6 16 1 9 2 0 7 6 3 10 14 16
%  6.8 3.7 5.6 1.9 4.3 3.7 9.9 0.6 5.6 1.2 0.0 4.3 3.7 1.9 6.2 8.6 9.9
ASCUS (n = 125)
N 5 5 2 1 8 11 9 2 4 2 1 5 4 2 3 26 2
%  4 4 1.6 0.8 6.4 8.8 7.2 1.6 3.2 1.6 0.8 4 3.2 1.6 2.4 20.8 1.6
LSIL  (n = 213)
N 18 12 13 4 32 19 18 5 4 6 3 9 5 8 10 28 11
%  8.5 5.6 6.1 1.9 15.0 8.9 8.5 2.3 1.9 2.8 1.4 4.2 2.3 3.8 4.7 13.1 5.2
HSIL  (n = 68)
N 4 5 2 2 3 3 4 2 1 0 1 1 0 0 3 4 4
%  5.9 7.4 2.9 2.9 4.4 4.4 5.9 2.9 1.5 0.0 1.5 1.5 0.0 0.0 4.4 5.9 5.9
CxCa  (n = 14)
N 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0
%  7.1 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0
Total  (n = 582)
18 
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%  6.7 4.8 4.5 1.7 8.6 6.9 8.1 1.7 
n those with high-grade squamous intraepithelial lesions, and
00% (14/14) in cervical carcinoma patients (chi-square = 236.880,
 < 0.001). There was also a signiﬁcantly higher presence of high-
isk genotypes in HPV-positive samples with greater disease
everity (Table 1), ranging from 66.9% in patients negative for
ntraepithelial lesions, 76.4% in patients with atypical squamous
ells of undetermined signiﬁcance, 84.8% in those with low-grade
quamous intraepithelial lesions, 95.6% in those with high-grade
quamous intraepithelial lesions to 100% in cervical carcinoma
atients (chi-square = 34.294, p < 0.001).
The distribution of HPV genotypes is shown in Table 1. Overall,
he most prevalent genotypes were HPV 16 (38.1%), HPV 6 (19.6%),
PV 44/55 (12.5%), HPV 42 (12.0%), HPV 52 (11.5%), and HPV 18
10.3%). The genotype distribution signiﬁcantly differed among the
iagnostic groups (chi-square = 44.215, p < 0.001). For example, the
resence of HPV 16 and/or HPV 18 rose from 32.1% in patients neg-
tive for intraepithelial lesions to 75% in patients with high-grade
quamous intraepithelial lesions and 100% in cervical carcinoma
atients.10 5 22 15 13 26 73 33
 1.7 0.9 3.8 2.6 2.2 4.5 12.5 5.7
More than one genotype was  present in 58.1% of HPV-positive
samples. Among these cases, 24.7% harbored 2 genotypes, 11.2%
3 genotypes and 22.2% 4 or more genotypes. The rate of mul-
tiple infections also signiﬁcantly increased with the severity of
disease: 51.9% of the patients negative for intraepithelial lesions,
53.6% of the patients with atypical squamous cells of undeter-
mined signiﬁcance, 66.2% of those with low-grade squamous
intraepithelial lesions, 52.9% of those with high-grade squamous
intraepithelial lesions, and 71.4% of those with cervical carcinoma
(chi-square = 11.137, p = 0.025).
3.2. Comparison of HPV detection systems: HPV positivity
HPV positivity rates were signiﬁcantly higher for HPV Direct
Flow CHIP in the paired comparisons: 73.6% HPV Direct Flow CHIP
versus 67% LA (p = 0.039) and 62.4% HPV Direct Flow CHIP versus
42.6% HC2 (p < 0.001).
In the HPV Direct Flow CHIP versus LA set, the results were con-
cordant for 97 samples (70 HPV-positive and 27 HPV-negative by
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Table 2
Comparison of HPV positivity for each sub-set. Samples were classiﬁed by cytological diagnosis and HPV positivity, percentage of overall and solely positive agreement, Kappa
index,  and McNemar test. LA, Linear Array HPV Genotyping Test; CLART, GENOMICA CLART HPV2; HC2, Hybrid Capture 2. Cytology category (Bethesda): NILM (negative
for  intraepithelial lesion or malignancy); ASCUS (atypical squamous cells of undetermined signiﬁcance); LSIL (low-grade squamous intraepithelial lesion); HSIL (high-grade
squamous intraepithelial lesion); CxCa (cervical carcinoma).
n HPV Direct Flow CHIP vs other systems Agreement (%) Positive agreement (%) Kappa McNemarp-value
+/+ +/− −/+ −/−
HPV Direct Flow CHIP vs. LA
NILM 61 28 7 1 25 86.9 77.8 0.74 0.07
ASCUS  3 1 0 0 2 100 100 1 1
LSIL  30 29 1 0 0 96.7 96.7 – –
HSIL  12 12 0 0 0 100 100 – –
CxCa  0 0 0 0 0 – – – –
Total  106 70 8 1 27 91.5 88.6 0.798 0.039
HPV  Direct Flow CHIP vs. CLART
NILM 46 21 2 1 22 93.5 87.5 0.870 1
ASCUS  16 8 3 0 5 81.3 72.7 0.625 0.25
LSIL  16 15 1 0 0 93.8 93.8 – –
HSIL  4 4 0 0 0 100 100 – –
CxCa  0 0 0 0 0 – – – –
Total  82 48 6 1 27 91.5 87.3 0.818 0.125
HPV  Direct Flow CHIP vs. HC2
NILM 73 17 19 0 37 74 47.2 0.48 <0.001
ASCUS  8 6 1 0 1 87.5 85.7 0.6 1
LSIL  14 14 0 0 0 100 100 – –
HSIL  5 5 0 0 0 100 100 – –
CxCa  1 1 0 0 0 100 100 – –
0.2 
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ote: In the “HPV Direct Flow CHIP vs. LA” set, 2 samples were excluded from the co
oth methods) and discrepant for 9 samples; the overall agree-
ent was 91.5%, the concordance for positive samples was  88.6%
Table 2), and the Kappa index showed substantial agreement
K = 0.798). Signiﬁcant differences were found in HPV detection
p = 0.039), with 78 positive cases detected by HPV Direct Flow CHIP
ersus 71 by LA. With respect to the diagnostic group, HPV detection
as the same by both methods in patients with high-grade squa-
ous intraepithelial lesions, while more HPV-positive cases were
etected by HPV Direct Flow CHIP than by LA in patients negative
or intraepithelial lesion and in those with atypical squamous cells
f undetermined signiﬁcance. The lowest agreement (<90%) was
btained in patients negative for intraepithelial lesions.
In the HPV Direct Flow CHIP versus CLART set, the results were
oncordant for 75 samples (48 HPV-positive and 27 HPV-negative
y both methods) and discrepant for 7 samples (Table 2). Overall
greement was 91.5%, and the Kappa value indicated almost perfect
greement (K = 0.818), with no signiﬁcant difference between HPV
irect Flow CHIP and CLART (p = 0.125). The results were highly
oncordant, especially in the cases with low- and high-grade squa-
ous intraepithelial lesions. More positive samples were detected
y HPV Direct Flow CHIP than by CLART in the cases negative for
ntraepithelial lesions and in the cases with atypical squamous
ells of undetermined signiﬁcance, but this difference was not
igniﬁcant.
able 3
omparison of multiple infection rates detected by the three different genotyping metho
ENOMICA CLART HPV2.
n (%), single vs. multiple infection d
HPV Direct Flow CHIP vs. Linear Ar
DF 
Undetermined genotype 1 (1.3%) 
Single  infection 29 (37.2%) 
Multiple infection 48 (61.6%) 
Two  genotypes 21 (26.9%) 
Three  genotypes 8 (10.3%) 
≥Four  genotypes 19 (24.4%) 68.2 0.618 <0.001
ison because the internal ampliﬁcation control was not positive in the LA test.
The results of the HPV Direct Flow CHIP and HC2  systems
were concordant for 43 HPV-positive and 38 HPV-negative samples
(Table 2). In the other 20 samples (19 negative for intraepithelial
lesions and 1 case of atypical squamous cells of undetermined sig-
niﬁcance), all were HPV-negative by HC2, whereas 11 were positive
for high-risk, 3 positive for high-risk + low-risk, and 6 for low-risk
HPV genotypes by HPV Direct Flow CHIP. Out of these 20 discord-
ant cases, 7 were patients with a known history of cervical lesions,
HPV persistence, and conization within the previous four years, and
these were all high-risk positive by HPV Direct Flow CHIP and HPV-
negative by HC2. In addition, 14 cases that were high-risk positive
by HC2 were high-risk + low-risk positive by HPV Direct Flow CHIP.
Although HC2 detects low-risk HPV 6, 11, 42, 43 and 44 genotypes,
one of these genotypes was  detected in 7 cases by HPV Direct Flow
CHIP but not by HC2.
3.3. Comparison of HPV detection systems: multiple infection
rates
Multiple infection rates in positive samples were 61.6% by HPV
Direct Flow CHIP versus 50.7% by LA and 61.1% by HPV Direct
Flow CHIP versus 40.8% by CLART (Table 3). HC2 does not distin-
guish between multiple and single infections and was  therefore
not included in these comparisons.
ds: DF, HPV Direct Flow CHIP; LA, Linear Array HPV Genotyping Test; and CLART,
etected in each sub-set
ray HPV Direct Flow CHIP vs. CLART
LA DF CLART
0 (0%) 2 (3.7%) 0 (0%)
35 (49.3%) 19(35.2%) 29 (59.2%)
36 (50.7%) 33 (61.1%) 20 (40.8%)
15 (21.1%) 16 (29.6%) 11 (22.5%)
12 (16.9%) 4 (7.4%) 3 (6.1%)
9 (12.7%) 13 (24.1%) 6 (12.2%)
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Table  4
Comparison of speciﬁc genotype detection, calculating the percentage of samples classiﬁed by result, percentages of overall and positive agreement, Kappa index and
McNemar test. Italics indicate genotypes that were only detected by one test and therefore not compared. (A) HPV  Direct Flow CHIP (DF) vs. Linear Array HPV  Genotyping
Test  (LA), calculated for the 69 HPV positive samples (one sample positive for the HPV-consensus probe but negative for all genotypes in the HPV Direct CHIP panel was
excluded from this comparison). (B) HPV Direct Flow CHIP (DF) vs. GENOMICA CLART HPV2 (CLART), calculated for the 47 HPV positive samples (one sample positive for the
HPV-consensus probe but negative for all genotypes in the HPV Direct CHIP panel was excluded from this comparison).
(A) DF+/LA+ DF+/LA− DF−/LA+ DF−/LA− Agreement Positive agreement Kappa Mc  Nemar
n % n % n % n % (%) (%) p-value
6 1 1.45 2 2.9 0 0 66 95.65 97.1 33.33 0.489 0.5
11  1 1.45 1 1.45 0 0 67 97.1 98.55 50 0.66 1
16  18 26.1 3 4.3 0 0 48 69.6 95.65 85.71 0.893 0.25
18  2 2.9 3 4.3 0 0 64 92.8 95.65 40 0.553 0.25
26  0 0 0 0 1 1.45 68 98.55 98.55 – – –
31  5 7.25 2 2.9 0 0 62 89.86 97.1 71.43 0.818 0.5
33  3 4.35 1 1.45 3 4.35 62 89.86 94.2 42.86 0.57 0.625
35  2 2.9 5 7.25 0 0 62 89.86 92.75 28.57 0.418 0.063
39  4 5.8 1 1.45 0 0 64 92.75 98.55 80 0.881 1
40  1 1.45 1 1.45 0 0 67 97.1 98.55 50 0.66 1
42  11 15.94 3 4.35 0 0 55 79.71 95.65 78.57 0.854 0.25
43  0 0 3 4.35 0 0 66 95.65 95.65 – – –
45  3 4.35 0 0 0 0 66 95.65 100 100 1 1
51  3 4.35 0 0 1 1.45 65 94.2 98.55 75 0.85 1
52  5 7.25 1 1.45 0 0 63 91.3 98.55 83.33 0.901 1
53  8 11.59 2 2.9 2 2.9 57 82.61 94.2 66.67 0.766 1
54  7 10.14 5 7.25 0 0 57 82.61 92.75 58.33 0.698 0.063
56  4 5.8 3 4.35 1 1.45 61 88.41 94.2 50 0.636 0.625
58  4 5.8 0 0 1 1.45 64 92.75 98.55 80 0.881 1
59  2 2.9 2 2.9 2 2.9 63 91.3 94.2 33.33 0.469 1
61  2 2.9 1 1.45 0 0 66 95.65 98.55 66.67 0.793 1
66  5 7.25 2 2.9 2 2.9 60 86.96 94.2 55.56 0.682 1
67  0 0 4 5.8 0 0 65 94.2 94.2 0 – –
68  2 2.9 4 5.8 1 1.45 62 89.86 92.75 28.57 0.41 0.375
69  0 0 0 0 0 0 69 100 100 – – –
70  3 4.35 1 1.45 0 0 65 94.2 98.55 75 0.85 1
71  2 2.9 1 1.45 0 0 66 95.65 98.55 66.67 0.793 1
72  0 0 0 0 0 0 69 100 100 – – –
73  1 1.45 0 0 0 0 68 98.55 100 100 1 1
82MM4 1 1.45 1 1.45 0 0 67 97.1 98.55 50 0.66 1
82IS39 0 0 0 0 1 1.45 68 98.55 98.55 – – –
83  0 0 0 0 4 5.8 65 94.2 94.2 0 – –
84  3 4.35 0 0 5 7.25 61 88.41 92.75 37.5 0.515 0.063
89  6 8.7 2 2.9 2 2.9 59 85.51 94.2 60 0.717 1
44/55  0 0 3 4.3 0 0 66 95.7 95.65 0 – –
62/81  9 13.04 5 7.25 1 1.45 54 78.26 91.3 60 0.699 0.219
(B)  DF+/CLART+ DF+/CLART− DF−/CLART+ DF−/CLART− Agreement Positive agreement Kappa Mc  Nemar
n % n % n % n % (%) (%) p-value
6 2 4.26 2 4.26 0 0 43 91.49 95.74 50 0.647 0.50
11  0 0 1 2.13 0 0 46 97.87 97.87 0 – –
16  6 12.77 2 4.26 4 8.51 35 74.47 87.23 50 0.589 0.687
18  2 4.26 1 2.13 0 0 44 93.62 97.87 66.67 0.789 1
26  0 0 0 0 0 0 47 100 100 – – –
31  6 12.77 1 2.13 2 4.26 38 80.85 93.62 66.67 0.762 1
33  2 4.26 1 2.13 2 4.26 42 89.36 93.62 40 0.538 1
35  2 4.26 4 8.51 0 0 41 87.23 91.49 33.33 0.466 0.125
39  1 2.13 0 0 0 0 46 97.87 100 100 1 1
40  0 0 0 0 0 0 47 100 100 – – –
42  5 10.64 4 8.51 0 0 38 80.85 91.49 55.56 0.669 0.125
43  0 0 2 4.26 0 0 45 95.74 95.74 0 – –
45  3 6.38 3 6.38 0 0 41 87.23 93.62 50 0.636 0.25
51  3 6.38 1 2.13 0 0 43 91.49 97.87 75 0.846 1
52  5 10.64 0 0 0 0 42 89.36 100 100 1 1
53  5 10.64 1 2.13 0 0 41 87.23 97.87 83.33 0.897 1
54  1 2.13 2 4.26 0 0 44 93.62 95.74 33.33 0.484 0.5
56  2 4.26 0 0 0 0 45 95.74 100 100 1 1
58  3 6.38 1 2.13 2 4.26 41 87.23 93.62 50 0.632 1
59  0 0 0 0 1 2.13 46 97.87 97.87 0 – –
61  2 4.26 0 0 0 0 45 95.74 100 100 1 1
66  5 10.64 1 2.13 0 0 41 87.23 97.87 83.33 0.897 1
67  0 0 5 10.64 0 0 42 89.36 89.36 – – –
68  1 2.13 4 8.51 0 0 42 89.36 91.49 20 0.309 0.125
70  3 6.38 1 2.13 0 0 43 91.49 97.87 75 0.846 1
71  0 0 0 0 1 2.13 46 97.87 97.87 0 – –
72  1 2.1 1 2.1 0 0 45 95.7 97.87 50 0.657 1
73  1 2.13 1 2.13 0 0 45 95.74 97.87 50 0.657 1
82MM4 0 0 1 2.13 3 6.38 43 91.49 91.49 0 −0.033 0.625
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Table 4 (Continued)
(B) DF+/CLART+ DF+/CLART− DF−/CLART+ DF−/CLART− Agreement Positive agreement Kappa Mc  Nemar
n % n % n % n % (%) (%) p-value
83 0 0 0 0 2 4.26 45 95.74 95.74 – – –
84  1 2.13 0 0 0 0 46 97.87 100 100 1 1
89  0 0 4 8.51 0 0 43 91.49 91.49 0 – –
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M44/55 2 4.26 6 12.77 0 0 39 
62/81 7 14.89 1 2.13 0 0 39 
The McNemar test was used to study the differences between
ethods in detecting “single infection” or “two or more geno-
ypes”. LA and HPV Direct Flow CHIP detected the same genotypes
n 19 samples with single infections and in 32 samples with two
r more genotypes. However, signiﬁcantly higher rates of multi-
le infection were found by HPV Direct Flow CHIP, which detected
ultiple genotypes in 14 samples identiﬁed as single infections by
A (p = 0.031). CLART and HPV Direct Flow CHIP detected the same
enotypes in 14 samples with single infections and in 18 with two
r more genotypes. However, signiﬁcantly higher rates of multiple
nfection were detected by HPV Direct Flow CHIP (p = 0.007), which
videnced multiple genotypes in 13 samples identiﬁed as single
nfections by CLART.
.4. Comparison of HPV detection systems: genotype-speciﬁc
ositivity
A good agreement in the genotype distribution was  observed
etween HPV Direct Flow CHIP and the other systems, especially
A (Table 4A and B). However, discrepant results were observed for
peciﬁc genotypes. Thus, in comparison to LA, HPV Direct Flow CHIP
howed a signiﬁcantly higher detection rate for HPV 18, 35, 44/55,
4, 67, and 68 but a signiﬁcantly lower detection rate for HPV 33
nd 84 genotypes; and, in comparison to CLART, HPV Direct Flow
HIP had a signiﬁcantly higher detection rate for HPV 6, 35, 42, 43,
4/55, 45, 54, 67, 68, and 89 but a lower detection rate for HPV 16,
lthough statistical signiﬁcance was not reached.
. Discussion
This study evaluated the HPV Direct Flow CHIP system, an auto-
atic assay for the sensitive detection and identiﬁcation of 36
ucosal HPV genotypes. The performance of the new system was
tudied by analyzing of 947 cervical samples. In addition, three sub-
ets of the studied population were also tested by other commercial
ethods commonly used in routine HPV detection, and the results
ere compared.
The most frequent high-risk HPV genotypes detected by HPV
irect Flow CHIP in the 947 cervical samples studied were HPV 16,
2, 18, 31, and 66. The same ﬁnding was reported by a recent study
hat used INNO-LiPA in samples from Spanish women attending
ervical cancer screening (Castellsague et al., 2012), despite the dif-
erence in HPV testing method and in the ampliﬁed L1 region (SPF10
n INNO-LIPA versus [GP5+/GP6+]-based in HPV Direct Flow CHIP).
he most prevalent high-risk genotypes in the patients negative
or intraepithelial lesions were HPV 16, 18, 68, 52, 45, 56, and 31,
hich is very similar to the distribution described for women with
ormal cytological ﬁndings worldwide (Bruni et al., 2010). Certain
enotypes were more frequent in early stages of the disease than
n carcinomas and vice versa. For instance, HPV 16 was detected in
2.2% (36/162) of HPV-positive patients negative for intraepithe-
ial lesions but in 78.6% (11/14) of HPV-positive cervical carcinoma
atients. These data are in agreement with previous reports on the
enotype distribution in invasive cervical cancer internationally (Li
t al., 2011) and in Spanish populations (Castellsague et al., 2012;
artin et al., 2011).82.98 87.23 25 0.356 0.031
82.98 97.87 87.50 0.921 1
HPV Direct Flow CHIP yielded signiﬁcantly higher rates of HPV
infection than the other methods used in this study, especially in
patients negative for intraepithelial lesions. It should be taken into
account that this sub-group included cases with cellular abnor-
malities other than intraepithelial lesions (e.g., cervicitis, history of
abnormal cytology, post-conization patients, etc.) and were there-
fore more prone to harbor viral infections.
HPV Direct Flow CHIP showed a very high concordance with the
LA, CLART, and HC2 systems in the pair-matched results (88.6%,
87.3%, and 68.2%; Kappa value 0.798, 0.818, and 0.618, respec-
tively). Despite the high agreement between HPV Direct Flow CHIP
and CLART in the 82 liquid-based cytology samples, a pilot compari-
son in 23 formalin-ﬁxed parafﬁn-embedded samples demonstrated
that HPV Direct Flow CHIP had a much higher sensitivity than CLART
in this type of material (K = 0.233) (data not shown). Low HPV detec-
tion rates in formalin-ﬁxed parafﬁn-embedded samples have been
described for the CLART system (Perez et al., 2012), and they have
been attributed to the low quality, cross-linkage, and fragmenta-
tion of the input DNA from these materials and to the use of PGMY
primers (Biedermann et al., 2004). In the case of the HPV Direct
Flow CHIP, the HPV amplicon size (approx. 150 bp) is smaller than
in the PGMY-based CLART assay (approx. 450 bp) and the PCR mix
is formulated to minimize PCR inhibition by cellular proteases or
chemicals in the sample medium or container, even when direct
PCR is used with formalin-ﬁxed parafﬁn-embedded tissue sections,
improving the HPV detection rates of HPV Direct Flow CHIP in this
type of sample.
Given that the systems mainly differed in the cases negative for
intraepithelial lesions and in the cases with atypical squamous cells
of undetermined signiﬁcance and were almost perfect agreement
in the cases with high-grade squamous intraepithelial lesions and
cervical carcinoma, it can be speculated that HPV Direct Flow CHIP
is more effective than the other HPV detection methods in sam-
ples with a low viral load. This idea is supported by the excellent
analytical performance of the test in the 2011 WHO  HPV LabNet
HPV DNA proﬁciency panel. Although the clinical relevance of a
low-dose infection has not yet been elucidated, it was an indicator
of viral persistence in some of the present patients. Thus, in the
sub-set of HPV Direct Flow CHIP versus HC2, seven patients with a
history of conization and HPV persistence in the previous four years
had a normal Pap smear at the time of the study and were HPV-
negative by HC2, but they were positive when investigated by HPV
Direct Flow CHIP and for the same genotype previously detected
in the same patients. This differential outcome of HPV testing may
be crucial for the sensitive evaluation of viral persistence/clearance
and for the follow-up of patients with a history of abnormal cytol-
ogy. However, further prospective studies are needed to evaluate
the clinical implications of these ﬁndings.
HPV Direct Flow CHIP resulted in signiﬁcantly higher detection
rates for 12 genotypes (HPV 18, 35, 44/55, 54, 67, and 68 with
respect to LA and HPV 6, 35, 42, 43, 44/55, 45, 54, 67, 68, and
89 with respect to CLART), while LA was more effective in the
identiﬁcation of HPV 33 and 84 and CLART detected two  more
cases positive for HPV 16. These differences in genotype-speciﬁc
sensitivity among HPV Direct Flow CHIP, LA, and CLART were
also observed in the 2011 WHO  HPV LabNet Proﬁciency Study,
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hile the four [GP5+/GP6+]-based methods included in the Lab-
et program (Luminex HPV Genotyping – Multimetrix/Progen;
ANArray; Digene HPV genotyping RH Test – Qiagen; and HPV
irect Flow CHIP) showed a very high genotype-speciﬁc agreement
manuscript in preparation). Discrepancies in both genotype- and
ariant-speciﬁc detection were expected in the present study, as
he tests differ in the viral target sequences for ampliﬁcation, PCR
etup, oligoprobe design, and hybridization conditions. The LA
nd CLART systems include PGMY-based ampliﬁcation, while HPV
irect Flow CHIP uses GP5+/GP6+ primers. Thus, the three methods
sed in the present study are based on broad-spectrum primers
nstead of genotype-speciﬁc ampliﬁcation, producing competition
nd the preferential ampliﬁcation of certain genotypes due to
istinct primer-target afﬁnities, especially in low viral load and/or
ultiple infection scenarios (Gillio-Tos et al., 2006).
In addition, the multiple infection rates were higher in HPV
irect Flow CHIP than in LA or CLART, reﬂecting its higher ana-
ytical sensitivity. This improved detection of multiple genotypes
er sample has already been observed for other highly sensitive
PV detection systems (Garcia et al., 2011; Schmitt et al., 2010;
oto-De Leon et al., 2011), and their presence has been proposed
s a possible biomarker of cervical dysplasia progression (Li et al.,
011), although further research is required. In the present study,
he multiple infection rate was higher with a more severe diagnosis,
s documented in a Columbian population screened using a highly
ensitive multiplex PCR and Luminex system (Garcia et al., 2011).
Finally, this study demonstrated the good performance of the
PV Direct Flow CHIP system for HPV testing in different types of
ample, using crude-cell extracts as the DNA template for ampliﬁ-
ation. It is important to note that the lack of a reference method
or general comparison and the use of three different groups for
airwise analysis limit the conclusions that can be drawn from
his study, and the performance of this system has yet to be thor-
ughly examined. Surveys in larger populations that include intra-
nd inter-laboratory determinations and comparisons with a gold-
tandard method are required for the optimal characterization of
his test.
In conclusion, comparative results obtained in this pilot study
emonstrated that the performance of HPV Direct Flow CHIP is
imilar to that of LA, CLART, and HC2. Given that it offers direct
CR from clinical specimens without a DNA puriﬁcation step, this
ovel test may  be a valuable tool for automated, rapid, and sensi-
ive HPV genotyping, especially in large-scale vaccine surveillance
nd epidemiology studies.
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